Literature DB >> 18712700

Head and neck manifestations of lymphogranuloma venereum.

Diana T Albay1, Glenn E Mathisen.   

Abstract

Lymphogranuloma venereum (LGV)--caused by Chlamydia trachomatis serovars L1, L2, or L3--rarely occurs in the United States. The disease clinically manifests in three stages: primary, secondary, and tertiary. The primary manifestation, a self-limited genital ulcer at the site of inoculation, often is absent by the time the patient seeks medical attention. The most common clinical manifestation of LGV is evident in its secondary stage: unilateral tender inguinal and/or femoral lymphadenopathy. However, proctocolitis or inflammatory involvement of perirectal or perianal lymphatic tissues resulting in fistulas and strictures may also occur. The diagnosis of LGV is usually made serologically and by exclusion of other causes of inguinal lymphadenopathy or genital ulcers. Doxycycline is the preferred treatment; it cures the infection and prevents ongoing tissue damage. This case highlights an unusual manifestation of LGV infection--cervical lymphadenopathy following suspected oropharyngeal infection with C trachomatis. Head and neck manifestations of LGV may become an increasing problem in the future if sexual practices such as orogenital contact become more widespread.

Entities:  

Mesh:

Year:  2008        PMID: 18712700

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  2 in total

1.  Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicentre case-control study in the U.K.

Authors:  S N S Pallawela; A K Sullivan; N Macdonald; P French; J White; G Dean; A Smith; A J Winter; S Mandalia; S Alexander; C Ison; H Ward
Journal:  Sex Transm Infect       Date:  2014-03-31       Impact factor: 3.519

Review 2.  Chlamydia trachomatis in Cervical Lymph Node of Man with Lymphogranuloma Venereum, Croatia, 20141.

Authors:  Branimir Gjurašin; Snježana Židovec Lepej; Michelle J Cole; Rachel Pitt; Josip Begovac
Journal:  Emerg Infect Dis       Date:  2018-04       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.